CTOs on the Move

Scripps Translational Science Institute

www.stsiweb.org

 
The Scripps Translational Science Institute (STSI) at The Scripps Research Institute (TSRI) aims to replace the status-quo of one-size-fits-all-medicine with individualized health care that is based on the known genetic factors influencing health and disease and that takes advantage of advances in digital technology for real-time health monitoring.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.stsiweb.org
  • 3344 North Torrey Pines Court Suite 300
    La Jolla, CA USA 92037
  • Phone: 858.784.2028

Executives

Name Title Contact Details

Funding

Scripps Translational Science Institute raised $34M on 05/02/2018

Similar Companies

bioMerieux

A world leader in the field of in vitro diagnostics for more than 50 years, bioMérieux is present in more than 150 countries through 42 subsidiaries and a large network of distributors. In 2015, revenues reached €1.965 billion with 90% of sales outside of France. bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

Ceregene

Ceregene is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Viacord

Viacord is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

emcresearch

emcresearch is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bio-Path Holdings

Bio-Path is a biotechnology company developing targeted therapies for acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and other challenging cancers. The company`s lead product candidate, prexigebersen (Liposomal Grb2 Antisense), formerly BP1001, is currently being assessed in a Phase 2 clinical study in 54 people with previously untreated AML who are not eligible for or who have decided to forego intensive induction therapy because of their age or fragile health.